Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Het bod is officiëel

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Het bod is officiëel

32 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. [verwijderd] 21 december 2010 08:53
    Johnson & Johnson has offered to purchase all of the outstanding American Depositary shares of Crucell N.V.

    The terms of the offer are as follows:

    Tender ADS for cash: USD equivalent of EUR 24.75 per ADS

    Shareholders then have the option to tender their holding with or without granting a Proxy that will allow the Offeror or its designees to vote such shares at the Post Offer Meeting in favour of approving a resolution to transfer the business of Crucell to the Offeror or an affiliate and to enter into the Business Purchase Agreement. The choice of proxy upon tendering your shares is irreversible.

    Please refer to the offer documentation for more detail regarding the Business Purchase Agreement and tendering with proxy/without proxy.

    The deadline to tender shares to the offer will be 2011-02-15 @ 13:00 ET.
  2. guyvg1 21 december 2010 10:30
    Vorige week een bericht ontvangen van mijn broker dat ik uiterlijk op 14/02/2011 moet beslissen om:

    1. in te gaan op het bod tegen biedprijs 24.75 euro per aandeel
    2. niet in te gaan op bod.

    Reageer ik niet, dan wordt geen actie ondernomen.

    Ik wacht af tot begin februari om te beslissen.

    mvg
    guy
  3. ejvdheuvel 29 december 2010 10:49


    The Unwanted Acquisition

    Crucell (CRXL) is a biotechnology company that licenses proprietary technologies, such as the PER.C6, a human designer cell line to develop and manufacture biopharma products, it also offers MAbstract to discover drug targets and identify human antibodies and a variety of other discovery and manufacturing platforms. The company’s shares are up over 50% for the year on a bid from Johnson and Johnson (JNJ) to acquire the company, and I am not happy about it. Every so often you come across a company that truly meets all the investment criteria of you model.

    One of those companies was Crucell. I recommended purchasing more CRXL in July 2010 saying:

    I still believe this is the single best stock to own over the long term. It has a disruptive technology that will alter the way the industry discovers and manufactures drugs. It has relationships with the largest companies in the industry and has already been the target of an attempted takeover. Would buy more at these levels.

    This company was in the never sell category and I have owned shares for over 10 years since originally purchasing for around $6/share. I still believe if Crucell stays independent, the shares could reach over $90/share, equating to a $9-10 billion market valuation. Obviously, I am not the only one who believes there is value in Crucell and its technology, as Wyeth attempted to purchase the company before Wyeth was acquired by Pfizer (PFE), thankfully killing the deal. Now, Johnson & Johnson (JNJ) is doing the bidding and looks to be winning the asset of Crucell at roughly $32.50/share US.

    This stock was trading below $20/share only two months before JNJ made its bid at a 56% premium to the previous day’s close. I have very mixed emotions about this offer. Yes, it is a nice win in the markets, but I believe I can make much more if CRXL remains independent and I am allowed to participate as a shareholder. Buried in the giant JNJ I will never get that opportunity.

    There are some ‘rebel’ shareholders out there that agree with me and aren’t eager to tender their shares. There is already a small discount between the offer price of $32.50 US and current quote of just under $31 because of this dissenting body of shareholders. I am considering buying shares. The deal appears likely to go through, and at current prices that would give current share purchasers about a 4% gain, and if JNJ sweetens the deal a bit for the holdouts the gain could be bigger. If the deal falls apart I will be very thankful for any selloff in reaction. I’d then re-establish a serious position in Crucell.

    seekingalpha.com/article/243939-stock...
  5. pardon 29 december 2010 12:40
    quote:

    guyvg1 schreef:

    Vorige week een bericht ontvangen van mijn broker dat ik uiterlijk op 14/02/2011 moet beslissen om:

    1. in te gaan op het bod tegen biedprijs 24.75 euro per aandeel
    2. niet in te gaan op bod.

    Reageer ik niet, dan wordt geen actie ondernomen.

    Ik wacht af tot begin februari om te beslissen.

    mvg
    guy
    Gewoon afwachten wat van de Herk doet,niet aanbieden dus.
  10. Gala-diner 22 februari 2011 09:16
    Settlement

    In accordance with the terms of the Offer, Shareholders who accepted the Offer and validly tendered (or defectively tendered provided that such defect has been waived by the Offeror) their Shares on the terms and subject to the conditions and restrictions of the Offer prior to the expiration of the Offer will be paid on 25 February 2011.

    finance.yahoo.com/news/Johnson-Johnso...
  11. [verwijderd] 22 februari 2011 12:04
    Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
    Last update: 2/22/2011 2:00:00 AM

    NEW BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 22, 2011 /PRNewswire via COMTEX/ -- Johnson & Johnson (JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announce that Johnson & Johnson has completed the tender offer for Crucell N.V. (Crucell) and has declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group. Reference is made to the joint press release of Johnson & Johnson and Crucell dated 8 December 2010 announcing the recommended cash offer by Johnson & Johnson, through its indirect wholly-owned subsidiary JJC Acquisition Company B.V. (the Offeror), for all of the issued and outstanding ordinary shares (Ordinary Shares) in the capital of Crucell, including all Ordinary Shares represented by American depositary shares (ADSs), each ADS representing one Ordinary Share (Ordinary Shares and ADSs are referred to herein as the Shares and the holders of such Shares are referred to as the Shareholders) at an offer price of euro 24.75 per share (the Offer).

    Johnson & Johnson will commence, through the Offeror, a subsequent offering period to allow Shareholders who have not yet accepted the Offer to tender their Shares, as further described below. Johnson & Johnson encourages Shareholders who have not yet accepted the Offer to do so immediately. Highlights Johnson & Johnson declares the Offer unconditional Share Acceptance Level is 95.24% of the issued and outstanding share capital of Crucell Settlement of the Offer will take place on 25 February 2011 Remaining Shares can be tendered in a Subsequent Offering Period ending 8 March 2011 Offer unconditional All conditions in connection with the Offer, as described in the offer document dated 8 December 2010 (the Offer Document), have been satisfied. As a result, the Offer is declared unconditional (gestanddoening). Acceptances As of the expiration of the initial offering period, the Shares tendered in the Offer, together with Shares already held by the Johnson & Johnson Group and the Shares to be acquired through the purchase and exercise of options, amount to 84,520,377 Shares (of which 12,774,957 are represented by ADSs), representing approximately 95.21% of the issued share capital of Crucell (which includes treasury shares held by Crucell) and 95.24% of the issued and outstanding share capital of Crucell, in each case on a fully diluted basis. 81,380 of ADSs tendered remain subject to the guaranteed delivery procedures described in the Offer. All Shares that were validly tendered (or defectively tendered provided that such defect has been waived by the Offeror) and not properly withdrawn, on the terms and subject to the conditions and restrictions of the Offer, during the initial offering period have been accepted for payment
  13. [verwijderd] 23 februari 2011 10:26
    meldingen afm......

    www.afm.nl/nl/professionals/registers...

    22 feb 2011 Crucell N.V. R.H.P. Brus
    22 feb 2011 Crucell N.V. C. de Jong
    22 feb 2011 Crucell N.V. L. Kruimer
    22 feb 2011 Crucell N.V. J. Goudsmit
    22 feb 2011 Crucell N.V. C. Wilhelmsson
    22 feb 2011 Crucell N.V. Ph.M. Satow
    22 feb 2011 Crucell N.V. J.P. Oosterveld
    22 feb 2011 Crucell N.V. A. Hoevenaars
    22 feb 2011 Crucell N.V. S. Davis
    22 feb 2011 Crucell N.V. F. Waller
    22 feb 2011 Crucell N.V. G. Siber
    22 feb 2011 Crucell N.V. J. Shannon
    22 feb 2011 Crucell N.V. W. Burns
  16. wilb52 25 februari 2011 07:23
    quote:

    eee schreef op 22 februari 2011 16:05:

    Gelezen in de Amerikaanse media: Johnson & Johnson complete friendly takeover of Crucell: bit.ly/c78Oe6
    Vriendelijk??

    Met dank aan de Vlerk ,Van Zwerk.
    Wij, de voormalige aandeelhouders , worden hartelijk uitgelachen,
    voor de jarenlange steun.

    Zoals eerder vermeldt, kan de goednieuws-show beginnen .
    Het zal wel milestones regenen de komende 2 a 3 maanden.
    En niet gepubliceerde PB's , in grote getalen.
  18. wilb52 25 februari 2011 14:00
    quote:

    Kojo schreef op 25 februari 2011 12:19:

    Ik vrees net hetzelfde, een stroom aan positieve berichten. En dat allemaal op de kap van de kleine aandeelhouder die zijn stukje moet inleveren aan 24,75.
    Die is al begonnen!
    In Leiden vieren ze feest!!
    Niet leiden = in last ( 3 okt )
    Maar leiden = in LUST!

    Bah tot de derde macht.
  19. forum rang 8 aextracker 26 februari 2011 12:36
    De J & J wwaardering van Euro 24.75 op basis van 8 jaren koershistorie is een meer dan nette waardering voor CRXL.

    Ik snap de commotie alhier niet erg goed !

    Wanneer worden de CRXL aandelen die op tijd zijn aangemeld eigenlijk financieel vereffend met de voormalige bezitters?

    Tracker
  20. [verwijderd] 26 februari 2011 14:27
    quote:

    aextracker schreef op 26 februari 2011 12:36:

    De J & J wwaardering van Euro 24.75 op basis van 8 jaren koershistorie is een meer dan nette waardering voor CRXL.

    Ik snap de commotie alhier niet erg goed !

    Wanneer worden de CRXL aandelen die op tijd zijn aangemeld eigenlijk financieel vereffend met de voormalige bezitters?

    Tracker

    financiele vereffening pas in de verre toekomst NA uitgebreide procesvoering.
    Waardering op basis van 8 jaar koershistorie mag dan redelijk genoemd worden, als bekend gaat worden hoe de pipeline zich de komende 2 jaar ontwikkeld heeft is de waardering NU een lachertje ,uitgaande van de ontwikkelingen die Crucell de afgelopen 10 jaar heeft door gemaakt.

    ian
32 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 872,41 +0,68%
EUR/USD 1,0690 +0,36%
FTSE 100 8.033,42 +0,12%
Germany40^ 18.080,40 +1,23%
Gold spot 2.325,76 -0,06%
NY-Nasdaq Composite 15.451,31 +1,11%

Stijgers

VIVORY...
+35,26%
PROSUS
+3,92%
BAM
+3,73%
JUST E...
+3,32%
Vastned
+2,48%

Dalers

RANDST...
-6,58%
Akzo N...
-6,01%
NSI
-4,12%
FASTNED
-3,54%
AMG Cr...
-2,04%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!